Stacey Ripple, APRN
Psychiatric/Mental Health · Granville, OHNPI 1336709799
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,543 of the $4,527 with a category attached, or 78.3%. 20 manufacturers reported payments, led by Corium, LLC at 28.9% of the total. Reporting peaked in 2023 at $2,104 and has fallen 67.6% since, to $681 in 2025.
Across 208 payments — averaging $21.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corium, LLC$1K
- AbbVie$956
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$550
- Otsuka America Pharmaceutical, Inc.$390
- Supernus Pharmaceuticals, Inc.$303
- Lundbeck LLC$232
- plus $788 from 14 others
What the payments were for
- Consulting fees$1734%
- Speaking & faculty fees$80518%
- Food & beverage$3,54378%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Azstarys$978
How this compares
$4,527 in reported general payments places this provider in the 85th percentile of 1,808 psychiatric/mental health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 22 | $1,324 |
| Buspirone Hcl | 31 | $661 |
| Oxcarbazepine | 12 | $577 |
| Clozapine | 24 | $292 |
| Quetiapine Fumarate | 13 | $112 |
| Lamotrigine | 14 | $111 |
| Lorazepam | 12 | $64 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Granville
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Steven MatesDayton$121K
- Robert ParsonsYoungstown$119K
- Chriscia BaneChillicothe$115K
- Rachael McLaughlinMaple Heights$114K
- Danielle MorroneCanfield$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.